Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab

Rituximab (RTX) is a chimeric B-cell-depleting monoclonal antibody against CD-20 positive cells that has been approved for the induction and maintenance of granulomatosis with polyangiitis (GPA). Reports have identified RTX to cause drug-related psoriasis. Many theories of underlying pathways have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Alahmari, Hana S., Alhowaish, Nasser Y., Omair, Mohammed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855024/
https://www.ncbi.nlm.nih.gov/pubmed/31781463
http://dx.doi.org/10.1155/2019/5450863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855024/
https://www.ncbi.nlm.nih.gov/pubmed/31781463
http://dx.doi.org/10.1155/2019/5450863

Ejemplares similares